Events

The DIA Annual Meeting will feature 7,500 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related products working together to foster innovation and facilitate health and well-being worldwide.

Drug effect on the cardiac repolarization and the potential for drug induced arrhythmia has long been recognized as a public health issue. In November 2010 the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) ratified the ICH-E14 guidance in Japan. In compliance with the ICH-E14 requirements, a thorough QT (TQT) Study, or an alternative QT assessment program, must be provided in support of nearly all New Drug Applications (NDA) in Japan. The science of designing, conducting and analysing TQT studies and the experience of unning these programs in Japan are rapidly evolving.

At the Alzheimer’s Association International Conference, history never repeats itself. Every year, thousands of the world’s leading dementia researchers gather to share new discoveries and innovative ideas in a forum that defines the field. At AAIC 2013 in Boston, we’ll celebrate 25 years of progress while shaping the future of dementia science.

Controlled substances present special supply challenges when conducting clinical trials, especially when a study has dozens or even hundreds of sites around the globe. Inventory monitoring and management are even more complicated for international clinical trials as regulations vary among countries. Fortunately, new advances in Interactive Web/Voice Response technologies are making it easier to meet the controlled substance supply management challenge. This webinar will outline ways to meet the special needs of controlled substance studies.

The SCDM Annual Conference is the world's largest education event for clinical data managers and related professionals.

The 2013 Annual Meeting Program Committee, Co-Chaired by Drs. Vikram Arya and Honghui Zhou, will ensure a varied and outstanding program adhering to the College's commitment to excellence in science and education while permitting sufficient time to "network" with friends and colleagues. Topics should be of interest to not only clinical pharmacologists, but a broad range of healthcare professionals in academia, industry, government and private practice.

In October 2013, OCT New England will once again prove industry leadership in providing cutting-edge solutions and a phenomenal speaker faculty.

Building on last year’s roaring success, this year’s agenda has been compiled with the help of OCT New England Advisory Board, bringing unprecedented value to CROs, biotechnology and pharmaceutical companies alike.

Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. We learned in Monte Carlo of new pathways identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy.

The 12th annual Partnerships in Clinical Trials Congress will be held in Vienna, Austria. The conference will feature over 150 speakers from large, mid-size and small pharmaceutical companies as well as CROs and vendors covering topics focused on clinical development.

The American Society of Hematology (ASH) invites you to New Orleans, LA, for its 55th annual meeting. As the premier hematology event of the year, this meeting is an invaluable educational experience for all attendees.